Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis

Company Overview

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: $17.67 to $19.75
• 52-Week Range: N/A
• Volume: 8,375 shs
• Average Volume: 129,776 shs
• Market Capitalization: $384.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBMG Stock Analysis - Frequently Asked Questions

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) announced its earnings results on Monday, November, 9th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter.

What other stocks do shareholders of Cellular Biomedicine Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro Biotech (ADRO), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Bristol Myers Squibb (BMY) and Intellia Therapeutics (NTLA).

Company Calendar

• Last Earnings: 11/09/2020
• Today: 7/07/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CBMG
• CIK: 1378624
• Web: www.cellbiomedgroup.com
• Phone: 347-905-5663
• Fax: N/A
• Employees: 217
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -144.80%
• Return on Assets: -61.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.47
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $340 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 19,478,000
• Free Float: N/A
• Market Cap: $384.69 million
• Optionable: Optionable
• Beta: 1.35